While these drugs have demonstrated clinical efficacy, recent data from regulatory agencies and medical reports have raised serious concerns about adverse reactionsincluding reported ozempic deaths
Our patients may experience symptoms such as nausea, vomiting, diarrhea, decreased appetite, or constipation, especially in the first weeks of therapy
For a deeper dive, here are 3 podcast episodes covering GLP-1 drugs: Weight Loss by Prescription: Inside the GLP-1 Story on FUELED wellness + nutrition Interview with Robin Bone, MD, OB-GYN | Weight Loss in a Pill: The Truth Behind the Hype on FUELED wellness + nutrition Interview with Alisha Reed, PharmD | Weight Loss Drugs on FUELED wellness + nutrition For more personalized guidance, schedule a consult with one of Mollys Lifestyle Dietitians by emailing [email protected].
Balancing Innovation and Affordability in Anti-Obesity Medications: The Role of Alternative Weight Maintenance Program was published in Health Affairs Scholar in May 2024
"GLP-1 receptor agonist use was associated with a higher risk of clinically recorded alopecia, particularly non-scarring alopecia, in patients with type 2 diabetes, compared with SGLT-2 and DPP-4 inhibitors," write the researchers in their published paper
On the other hand, there are some clinical studies suggesting the association between GLP-1 related medicines and the increased risk of HF hospitalization [64,65,66,67]
